Crossmark Global Holdings Inc. bought a new position in Cantel Medical Corp. (NYSE:CMD) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 9,284 shares of the company’s stock, valued at approximately $874,000.
A number of other large investors also recently modified their holdings of CMD. First Trust Advisors LP raised its position in shares of Cantel Medical Corp. by 6.8% in the 3rd quarter. First Trust Advisors LP now owns 11,677 shares of the company’s stock valued at $1,100,000 after acquiring an additional 739 shares during the period. Aperio Group LLC raised its position in shares of Cantel Medical Corp. by 8.4% in the 3rd quarter. Aperio Group LLC now owns 13,894 shares of the company’s stock valued at $1,308,000 after acquiring an additional 1,075 shares during the period. Globeflex Capital L P acquired a new stake in shares of Cantel Medical Corp. in the 2nd quarter valued at approximately $114,000. LS Investment Advisors LLC acquired a new stake in shares of Cantel Medical Corp. in the 2nd quarter valued at approximately $172,000. Finally, Ingalls & Snyder LLC acquired a new stake in Cantel Medical Corp. during the 3rd quarter worth approximately $235,000. 85.16% of the stock is currently owned by hedge funds and other institutional investors.
Several analysts have commented on the stock. Needham & Company LLC restated a “hold” rating on shares of Cantel Medical Corp. in a report on Friday, September 1st. Zacks Investment Research raised shares of Cantel Medical Corp. from a “sell” rating to a “hold” rating in a research note on Tuesday, August 8th. Finally, Sidoti raised shares of Cantel Medical Corp. from a “neutral” rating to a “buy” rating and set a $92.00 price target for the company in a research note on Wednesday, August 2nd. Four equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $91.67.
In other Cantel Medical Corp. news, EVP Eric W. Nodiff sold 2,868 shares of Cantel Medical Corp. stock in a transaction on Friday, October 20th. The shares were sold at an average price of $97.55, for a total transaction of $279,773.40. Following the completion of the transaction, the executive vice president now directly owns 39,102 shares of the company’s stock, valued at $3,814,400.10. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Chairman Charles M. Diker sold 20,500 shares of Cantel Medical Corp. stock in a transaction on Wednesday, October 4th. The stock was sold at an average price of $99.15, for a total transaction of $2,032,575.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 36,368 shares of company stock valued at $3,576,028. Company insiders own 14.90% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Crossmark Global Holdings Inc. Buys Shares of 9,284 Cantel Medical Corp. (CMD)” was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be viewed at https://ledgergazette.com/2017/11/13/crossmark-global-holdings-inc-buys-shares-of-9284-cantel-medical-corp-cmd.html.
Cantel Medical Corp. (CMD) opened at $98.28 on Monday. The company has a current ratio of 2.41, a quick ratio of 1.49 and a debt-to-equity ratio of 0.24. Cantel Medical Corp. has a 52-week low of $69.21 and a 52-week high of $99.83. The company has a market cap of $4,100.98, a price-to-earnings ratio of 47.25 and a beta of 1.23.
Cantel Medical Corp. (NYSE:CMD) last released its quarterly earnings data on Thursday, September 28th. The company reported $0.54 EPS for the quarter, topping the Zacks’ consensus estimate of $0.52 by $0.02. Cantel Medical Corp. had a net margin of 9.27% and a return on equity of 17.60%. The firm had revenue of $205.50 million during the quarter, compared to analysts’ expectations of $200.32 million. The firm’s revenue for the quarter was up 14.8% on a year-over-year basis. equities analysts predict that Cantel Medical Corp. will post 2.34 EPS for the current year.
The business also recently disclosed a Semi-Annual dividend, which will be paid on Wednesday, January 31st. Shareholders of record on Wednesday, January 17th will be given a dividend of $0.085 per share. This represents a yield of 0.17%. This is a boost from Cantel Medical Corp.’s previous Semi-Annual dividend of $0.07. The ex-dividend date is Tuesday, January 16th. Cantel Medical Corp.’s payout ratio is 8.19%.
About Cantel Medical Corp.
Cantel Medical Corp. is a provider of infection prevention products and services in the healthcare market. The Company’s operating segments include Endoscopy; Water Purification and Filtration; Healthcare Disposables, and Dialysis. Its Endoscopy segment includes medical device reprocessing systems, disinfectants, detergents and other supplies.
Want to see what other hedge funds are holding CMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cantel Medical Corp. (NYSE:CMD).
Receive News & Ratings for Cantel Medical Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cantel Medical Corp. and related companies with MarketBeat.com's FREE daily email newsletter.